Abstract
Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is frequent and progresses to fibrosis among patients with diabetes. The roles of hepatic steatosis and of the accumulation of Advanced Glycation Endproducts (AGEs) can now be analyzed by new non-invasive methods. Patients and methods: Among hospitalized patients with diabetes, we assessed liver fibrosis by liver stiffness measurement (LSM), steatosis by the attenuation coefficient of an ultrasonic wave (CAP) and AGE accumulation by skin autofluorescence (sAF). The patients with severe fibrosis were compared to the others by ANOVA and Chi-2, and the relations between fibrosis, steatosis, and skin AF were studied by regression analysis. Results: 178 patients were included: 60% male, age 59 ± 11 years, BMI 31 ± 6 kg/m2, 79% with Type 2 Diabetes (T2D), poorly controlled (HbA1C 9.0 ± 2.4%). sAF were available in all patients, LSM in 139 and CAP in 93 subjects. Severe fibrosis (LSM>8.7 kPa) was evidenced in 32 (23%) patients, mainly T2D (n=31/32), with higher BMI and waist circumference (p<0.0001). They had higher CAP: 319 ± 53 dB/m (No fibrosis: 268 ± 59, p<0.005), whereas their sAF did not differ. LSM was correlated to the CAP (r=0.40, p<0.0001) and the waist circumference (r=0.46, p<0.0001), but not to sAF. CAP was related to waist circumference and triglycerides level (r=0.70 in multivariate analysis). 1.4 Conclusion: More steatosis and similar skin autofluorescence in patients with diabetes and severe liver fibrosis support that steatosis promotes fibrosis, and suggests that AGEs do not accelerate this progression.
Highlights
Non Alcoholic Fatty Liver Disease (NAFLD) is frequent and progresses to fibrosis among patients with diabetes
In 178 patients hospitalized for their poorly controlled diabetes, we measured the skin autofluorescence (sAF), and we proposed a non-invasive screening for NAFLD; liver fibrosis was assessed by the liver stiffness measurement (LSM), and steatosis by the Controlled attenuation parameter (CAP)
We measured the sAF and we proposed a non-invasive screening for NAFLD
Summary
Non Alcoholic Fatty Liver Disease (NAFLD) is frequent and progresses to fibrosis among patients with diabetes. Non Alcoholic Fatty Liver Diseases (NAFLD) causes serious hepatic damage and can lead to fibrosis, cirrhosis and liver cancer [1]. Their natural history includes two phases: first the accumulation of triglycerides due to insulin resistance makes a vulnerable steatotic liver, and a second hit, involving oxidative stress, leads to inflammation and fibrosis [2]. These events are not clinically apparent, and diagnosis is delayed. Are the levels of steatosis high in patients with diabetes and hepatic fibrosis?
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
